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Background: Nephrotoxicity is one of the most important limitations of cisplatin-based 
chemotherapies which associated with many complications and high mortality rate. 
Objectives: To investigate the effect of lycopene on cisplatin-induced nephrotoxicity in 
patients with cancer.
Patients and Methods: In this double-blind, randomized clinical trial, 120 patients were 
randomly assigned to two groups, case (treated with lycopene + standard regimen of kidney 
injury prevention) and control (treated with only the standard regimen of kidney injury 
prevention). Lycopene was orally taken from 24 hours before to 72 hours after cisplatin 
administration. Blood urea nitrogen (BUN), serum creatinine (Cr), and glomerular 
filtration rate (GFR) were measured and recorded. The data were analyzed using SPSS.
Results: Changes in Cr were not significantly different between the two groups (P = 0.131). 
However, a significant decreasing trend was seen in GFR during the study, which was 
more marked in the control group (P = 0.004). BUN significantly decreased during the 
study (P = 0.002), and a significant decrease of BUN on the day three in both groups was 
seen (P = 0.001). However, BUN increased in the case group on the day 21 of treatment. 
The corresponding increase was less marked in the control group.
Conclusions: Lycopene can be considered a useful adjuvant therapy to decrease the 
complications due to cisplatin-induced nephrotoxicity in patients with cancer.
ABSTRACT
Implication for health policy/practice/research/medical education:
Lycopene can be effective in decreasing the complications due to cisplatin-induced nephrotoxicity through affecting some 
markers of  renal function. Therefore, use of  lycopene, at appropriate doses, can be considered an adjuvant therapy, alongside 
chemotherapy and complementary therapy, to decrease the effects of  nephrotoxicity.
Please cite this paper as: Mahmoodnia L, Mohammadi K, Masumi R. Ameliorative effect of  lycopene effect on cisplatin-induced 
nephropathy in patients. J Nephropathol. 2017;6(3):144-149. DOI: 10.15171/jnp.2017.25.
1. Background
Cis-diamminedichloroplatinum(II) [cis-(Pt(NH3)-
2Cl2), cisplatin)], commonly referred to as CDDP, 
is a synthetic and anticancer compound (1) which is 
used depending on the type and histological degree 
of  tumor, disease stage, and the patient’s tolerance to 
side effects (2). Cisplatin can damage both cancer and 
healthy cells and nephrotoxicity is one of  the compli-
cations due to cisplatin (3).
Risk of  nephrotoxicity due to cisplatin is an obstacle 
to using high doses of  this drug and hence achiev-
ing maximum therapeutic effect. Cisplatin can cause 
apoptosis of  renal proximal tubular cells (LLC-PK1) 
through activating mitochondrial pathways (4). There-
fore, frequent nephrotoxicity is one of  the most im-
portant limitations of  cisplatin-based chemotherapy 
which is associated with many complications and high 
mortality rate (5).
Cisplatin-induced nephrotoxicity occurs due to pro-
duction of  reactive oxygen species (ROS), especially 
hydroxyl radicals, which leads to lipids peroxidation, 
oxidation of  proteins, lipids, and nucleic acids, and 
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destruction of  cell membrane. Producing such free 
radicals causes decline in glomerular filtration rate 
(GFR), variations in some blood-based biomarkers, 
and incidence of  acute tubular nephrotoxicity. These 
complications occur mainly in proximal tubes (S3 
segment) (6,7). Cisplatin enters into renal epithelial 
cells and may cause damage to mitochondrial nuclear 
DNA compounds. Then, it may cause predisposition 
to apoptosis and necrosis via producing ROS and ac-
tivating mitochondrial and non-mitochondrial path-
ways (8).
Carotenoids, including lycopene, are very strong an-
tioxidants and can prevent the toxic effects of  oth-
er substances in the body (9). Carotenoids can react 
chemically with ROS and oxidize, and therefore pre-
vent cell damage due to ROS (10). However, simulta-
neous use of  antioxidant compounds and anticancer 
drugs is still being debated, because excessive use of 
antioxidant compounds can intervene in chemothera-
py and cancer treatment (11). Besides that, no amelio-
rate impacts have been obtained on the use of  antiox-
idants in some studies (12,13).
Despite oxidative agents play the most important role 
in renal tissue damage and cisplatin-induced nephro-
toxicity (14) and few studies have investigated this is-
sue in human beings. Thus, the role of  antioxidants 
should be investigated in preventing such damages. 
Some studies are seeking to detect the best protective 
agent for different tissues. 
The role of  lycopene has not yet been adequately 
studied in protecting against cisplatin-induced neph-
rotoxicity. Besides that, to the best of  our knowledge, 
no similar study has yet been conducted in Iran. 
2. Objectives
 Aim of  this study is to investigate the therapeutic and 
protective effects of  lycopene on cisplatin-induced 
nephrotoxicity in humans.
3. Patients and Methods
3.1. Patients
In this double-blind, randomized clinical trial, 120 
people were selected from the patients referring to 
the hematology and oncology clinic of  the Shahre-
kord University of  Medical Sciences by convenience 
sampling. The inclusion criteria were considered to 
be suffering cancer without primary involvement or 
renal metastasis, being candidate for administration 
of  70-100 mg/m2 cisplatin, 20-80 years old, creati-
nine (Cr) < 1.5 mg/dL, normal hearing, no underly-
ing nephropathy and the performance status of  0-2 
of  Karnofsky. Using random allocation software, we 
assigned the patients randomly to two groups of  cases 
and controls. The control group was received cisplatin 
and a standard regimen of  kidney injury prevention 
(hydration + magnesium sulfate).
The case group were administered lycopene+ cispla-
tin alongside a regimen of  kidney injury prevention 
(hydration + magnesium sulfate). Death, allergy to ly-
copene, hearing loss, significant neuropathy, and met-
astatic renal involvement were considered as exclusion 
criteria.
3.2. Intervention and biochemical measurements
Appropriate therapeutic doses of  cisplatin were in-
travenously administered to all the patients according 
to their body mass index and underlying disease(s) 
(15,16). Any patients of  the case group took a ly-
copene tablet (25 mg) each 12 hours from 24 hours 
before to 72 hours after cisplatin administration (17). 
To investigate cisplatin-induced nephrotoxicity, blood 
urea nitrogen (BUN), serum Cr (18), and GFR (19) 
were measured.
At the beginning of  the study and on the days 7 and 
21 after cisplatin administration, 5-cc blood sam-
ples of  the participants were taken for measurement 
of  BUN and Cr. Then, GFR was calculated with to 
Crockroft-Gault formula. 
3.3. Ethical considerations
1) The research followed the tenets of  the Declaration 
of  Helsinki; 2) informed consent was obtained, and 
3) the research was approved by the ethical commit-
tee of  Shahrekord University of  Medical Sciences (IR.
SKUMS.rec.1394.271). Besides that, the study proto-
col was registered as In the Iranian Registry of  Clinical 
Trials (IRCT2016050427745N1). 
3.4. Data analysis
The data were analyzed by SPSS 20 software. The 
quantitative variables were expressed as mean (stan-
dard deviation) or median (interquartile range) and 
qualitative variables as number (%). To compare quan-
titative variables, repeated measures analysis of  vari-
ance (ANOVA) was used and to compare qualitative 
variables, chi-square and, P < 0.05 was considered the 
level of  significance. 
4. Results
Overall, 120 patients participated in this study. Six-
ty patients, assigned as cases, received lycopene and 
a standard regimen of  kidney injury prevention and 
the rest, controls, received only the standard regi-
men of  kidney injury prevention. Fifty-eight (48.3%) 
participants were female. In the control group, 27 
(45%) and in the case group, 31 (57.7%) people were 
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female with no significant difference (P = 0.465). 
The age of  the patients in the case and control 
groups ranged 18-80 and 24-82 (mean: 56.5± 13.3 and 
58.5± 12) years, respectively, with no significant differ-
ence according to t test (P = 0.379).
The weight of  the patients in the case and control 
groups ranged 38-93 kg and 42-88 kg (mean: 64± 10.9 
and 66.7 ± 10.9), respectively, with no significant dif-
ference according to t test (P = 0.182).
The three renal function parameters, including Cr, 
GFR, and BUN measurement results, during the study 
in the two groups are shown in Table 1.
According to repeated measure ANOVA, the chang-
ing trend of  serum Cr was not significantly different 
between the two groups (P = 0.131), although this 
trend was significant throughout the study in both 
groups (P = 0.011). 
In addition, a significant change in GFR was seen 
throughout the study (P < 0.001) with a significant 
difference between the two groups (P = 0.004). A de-
creasing trend of  GFR was seen in the control group, 
however, GFR increased in the case group on the first 
three days and then decreased partially.
A significant change was seen in BUN throughout the 
study (P = 0.002) too. Additionally, a significant de-
crease in BUN was seen in both groups on the day 
three (P = 0.001), but BUN increased in the case group 
on the day 21, however, the corresponding increase 
was less marked in the control group. 
5. Discussion
In this study, GFR decreased throughout the study 
in the control group, but increased in the case group 
within the first three days and then slightly decreased. 
BUN had a significantly decreasing trend in both 
groups with a more marked decrease in the case 
group, maybe due to hydration. Besides that, a signif-
icant change was seen in Cr alongside the study with 
no significant difference between the two groups. 
In this regard, a study demonstrated that cisplatin ad-
ministration to mice is associated with nephrotoxicity, 
decreases the GFR, and an increase in Cr and plasma 
urea. This also caused renal dysfunction associated 
with increased malondialdehyde (MDA) concentra-
tion in renal tissue. Atessahin et al demonstrated that 
administration of  lycopene, before and after cisplatin 
administration, significantly protected kidneys against 
nephrotoxicity following cisplatin administration and 
improved the biomarkers in rats (20).
In the study of  Dogukan et al, the Cr and plasma urea 
levels were significantly lower in cisplatin + lycopene, 
administered group than cisplatin-administered group 
after the induction of  nephrotoxicity. Moreover, ly-
copene significantly prevented increase in MDA and 
caused decrease in lipids peroxidation in mice. Finally, 
they concluded that lycopene plays a protective role 
against nephrotoxicity after administration of  cispla-
tin (21). In the study of  Erman et al, mice were as-
signed to four groups, control, lycopene, cisplatin, and 
cisplatin+ lycopene.
Following nephrotoxicity induction, the findings in-
dicated that use of  lycopene, after cisplatin adminis-
tration, caused decrease in serum BUN, Cr, and other 
measured biomarkers. Thus, lycopene administration 
significantly resulted to protect kidneys against the 
complications due to use of  cisplatin (22).
A study was conducted to investigate the protective 
effect of  lycopene on ischemic reperfusion renal dam-
age in rats in the short term. After the induction of 
nephrectomy and perfusion ischemia in rats, the blood 
samples of  rats were investigated for renal biomark-
ers. Pektas et al found, the pathological score, MDA, 
glutathione, and catalase of  the control group were 
higher than those of  lycopene-treated group. There-
Table 1. The results of  renal function markers during the study
Variable Measurement step
Control group
(mean  ±  SD)
Case group
(mean  ±  SD)
Significance 
level between the 
groups
Significance 
level of  time 
effect
Significance level 
of  time and group 
interaction
Cr 
mg/dL
Baseline 1.00  ±  0.24 1.05 ± 0.23 0.261
0.011 0.131Day 3 1.00  ±  0.22 1.12 ± 0.65 0.416
Day 21 1.17 ± 0.51 1.09 ± 0.42 0.402
GFR 
cc/min
Baseline 72.06 ± 17.39 66.76 ± 18.75 0.112
<0.001 0.004Day 3 71.92 ± 17.17 69.22 ± 20.28 0.447
Day 21 65.01 ± 20.77 67.14 ± 20.10 0.587
BUN 
mg/dL
Baseline 26.62 ± 9.80 29.29 ± 9.25 0.129
0.002 <0.001Day 3 25.55 ± 7.72 16.17 ± 8.97 0.691
Day 21 30.74 ± 11.65 26.82 ± 9.72 0.059
Abbreviations: Cr, creatinine; GFR, glomerular filtration rate; BUN, blood urea nitrogen.
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fore, lycopene may have protective effects on kidney 
injuries and related surgeries (23).
In a study on the effect of  lycopene on mercuric 
chloride-induced nephrotoxicity in rats, the findings 
indicated that lycopene reduced the toxicity due to 
HgCl(2) through preventing lipids peroxidation and 
changing delta-aminolevulinate acid dehydratase, and 
antioxidant enzymes, although it could not prevent 
the kidney injury induced by HgCl(2) (24). 
Overall, antioxidant compounds can decrease the risk 
of  cisplatin-induced nephrotoxicity, which has been 
confirmed in this study and other researches. Lyco-
pene, an antioxidant, contributes to decreasing oxi-
dative stress and preventing cancer (25). The positive 
effects of  antioxidant compounds have already been 
demonstrated on cisplatin-induced nephrotoxicity. In 
a study on the effect of  capsaicin on cisplatin-induced 
nephrotoxicity, use of  capsaicin, an antioxidant and 
anti-inflammatory agent, was found to be effective in 
decreasing tissue damage and serum levels of  BUN 
and Cr (26).
Ju et al studied the effects of  apigenin, a flavonoid, on 
cisplatin-induced nephrotoxicity and proximal tubular 
epithelial cells, and found that apigenin caused de-
crease in P53 activity and therefore decline in apopto-
sis in renal cells (27). In another study, simvastatin and 
rosuvastatin was found to be effective in decreasing 
kidney injuries and lipids peroxidation due to cisplatin 
(28). A study on the effect of  epoxyeicosatrienoic ac-
ids on nephrotoxicity and the induction of  endoplas-
mic reticulum stress reported consistent findings, in-
dicating that this compound caused decrease in some 
blood-based biomarkers such as BUN and Cr through 
exerting antioxidant effects (29).
However, the study by Mazaheri et al demonstrated 
that Foeniculum vulgare essential oils had no effect on 
the serum levels of  urea and Cr, renal tissue damage, 
and kidneys weight (13). In addition, a study demon-
strated that not only did pomegranate flower extract 
protect mice against cisplatin-induced nephrotoxicity 
but it also exacerbated renal tissue damage, although 
this extract has antioxidant properties (12). This incon-
sistency can be due to various antioxidant capacities of 
different substances, lack of  extracting effective sub-
stances, and the interactions of  other substances with 
treatment course in other studies. 
Although antioxidant compounds can exert anti-in-
flammatory and anti-apoptotic effects on renal cells, 
the mechanism of  cisplatin anti-cancer effect is to 
induce cell toxicity and cell apoptosis. Excessive use 
of  antioxidants and associated supplements can inter-
vene in cancer treatment, as a review of  clinical trials 
reported that use of  antioxidant supplements during 
chemotherapy and radiotherapy helped to protect tu-
mor and hence reduced survival (11).
Therefore, excessive use of  these compounds pre-
vents this drug from acting efficiently and effective 
doses should be sought out. Use of  antioxidants is 
addressed as an approach to prevent cancer. Fight-
ing oxidative stress and free radicals, antioxidants 
can exert their preventive effects. As a result, antiox-
idants should be cautiously used to treat cancer and 
addressed as adjuvant therapies accompanying main 
treatments. 
6. Conclusions
Lycopene can be effective in decreasing the complica-
tions due to cisplatin-induced nephrotoxicity through 
affecting some markers of  renal function. Therefore, 
use of  lycopene, at appropriate doses, can be con-
sidered an adjuvant therapy, alongside chemotherapy 
and complementary therapy, to decrease the effects of 
nephrotoxicity. A limitation of  the present study was 
related to the biomarkers used to diagnose nephro-
toxicity. BUN and serum Cr may delay the diagnosis 
of  nephrotoxicity. Therefore, use of  other biomarkers 
seems necessary to diagnose nephrotoxicity early.
More biomarkers should be investigated and neces-
sary standards of  sensitivity and speed should be con-
sidered in the studies on nephrotoxicity. Furthermore, 
the effective doses of  lycopene in decreasing neph-
rotoxicity with no drug interactions should be sought 
out.
Limitations of  the study
This is a retrospective single-center study with a lim-
ited proportion of  patients. Thus, multi-centric stud-
ies on this titles suggests. Moreover, future studies are 
recommended to compare the effects of  different an-
tioxidant compounds on nephrotoxicity, to examine 
the effects of  lycopene on the long-term prognosis 
in patients, and to investigate potentially unknown in-
teractions.
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